ClinicalTrials.gg
Active, not recruitingNCT05983302Updated May 6, 2026

Elimination of Odor and Treatment of Malodorous Recalcitrant Wounds by Using Supraz and PRP-FG Versus Standard of Care

A Phase 2/3 interventional study of Platelet-Rich Plasma-Fibrin Glue and Repairing Gel in Wounds and Injuries, sponsored by Mashhad University of Medical Sciences. Active, not recruiting at 1 site in Iran. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Mashhad University of Medical Sciences · Phase 2/3, Interventional, and Treatment

Phase
Phase 2/3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Sex
All
01

Study summary

The aim of this study is to eliminate the malodorous of chronic wound and increase the chance of the healing of recalcitrant wounds by using the repairing gel (supraz gel) which has the approved components in wound healing and platelet-rich plasma-fibrin glue.

Read the detailed description

The current study assesses the effects of platelet-rich plasma-fibrin glue (PRP-FG) along with the use of the repairing gel which has the approved components on wound healing in patients with chronic wounds and to eliminate the malodorous of chronic wound. This randomized controlled trial is performed on patients with chronic wounds. Patients will be treated with repairing gel (supraz gel) plus PRP-FG dressing (intervention group) or only Supraz gel (intervention group) or only PRP-FG dressing (intervention group) every 48 hours for 8 weeks versus standard of care of treatment (control group: irrigation of wound by normal saline 0.9%).

02

Conditions studied

  • Wounds and Injuries

Browse trials for

Keywords

  • Platelet-Rich Plasma-Fibrin Glue
  • Repairing Gel
  • Chronic Wounds
  • Malodorous
  • Recalcitrant
03

In context

Wounds and Injuries

2,217 studies on the registry are indexed under Wounds and Injuries; 441 are open to participants now.

This study's planned enrollment of 40 is below the median of 70 across 1,424 interventional studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

Mashhad University of Medical Sciences is the lead sponsor of 92 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having a single wound on the body that has been at least 3 months old and has not been repaired by wound irrigation with normal saline and changing the dressing
  • Having a of 18-35
  • Sign the by the patient

Exclusion criteria

Exclusion Criteria:

  • Having concurrent diseases that may cause problems in wound healing, such as cancers, vasculitis, kidney and liver failure, and heart failure
  • Taking certain drugs that may interfere with wound healing, such as , agents, and cytotoxic agents
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Platelet-Rich Plasma-Fibrin Glue

    The first intervention group (group A) includes 10 patients with chronic wounds who, despite classic wound irrigation treatment, will be undergoing platelet-rich plasma-fibrin glue intervention for 8 weeks.

    Drug: Platelet-Rich Plasma-Fibrin Glue

  • Experimental
    Repairing Gel

    The second intervention group (group B) includes 10 patients with chronic wounds who, despite classic wound irrigation treatment, will be undergoing repairing gel intervention for 8 weeks. The components of repairing gel are vitamin A - vitamin C - vitamin B3 - glycine amino acid. - ethanol - collagen - citric acid - glycerin - malic acid - urea - carboxymethyl cellulose - Sodium alginate - Benzoic acid - Allantoin - Bromelain - Methylene blue - Violet dimethyl sulfoxide . The formulation is patented. (PCT, IR108458)

    Drug: Repairing Gel

  • Experimental
    Platelet-Rich Plasma-Fibrin Glue and Repairing Gel

    The third intervention group (group C) includes 10 patients with chronic wounds who, despite classic wound irrigation treatment, will be undergoing the repairing gel with approved wound healing components and platelet-fibrin glue for 8 weeks.

    Drug: Repairing Gel and Platelet-Rich Plasma-Fibrin Glue

  • Experimental
    Classical wound irrigation (control)

    For 10 patients with chronic wounds, only classical wound irrigation by normal saline (0.9%) will be continued for 8 weeks.

    Other: Classical wound irrigation (control)

Interventions

  • DrugPlatelet-Rich Plasma-Fibrin Glue

    The first intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone PRP-FG intervention for 8 weeks.

    Also known as: PRP-FG

  • DrugRepairing Gel

    The second intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel for 8 weeks.

    Also known as: Supraz Gel

  • DrugRepairing Gel and Platelet-Rich Plasma-Fibrin Glue

    The third intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel and PRP-FG for 8 weeks.

    Also known as: Supraz Gel and PRP-FG

  • OtherClassical wound irrigation (control)

    For 10 patients with chronic wounds, only the classical wound irrigation by normal saline will be continued for 8 weeks.

    Also known as: Control

06

What researchers measure

Primary outcomes

  1. Wound Odor Change

    Change from Baseline Wound Odor intensity at 2 months will be assessed by the nurse using a Visual Analog Scale (VAS) from 0 to 100 (perceived odor).

    Time frame: At the beginning of the study (0 day) and at the end of the eighth week of the intervention (8 weeks)

  2. Wound Size Change

    Change from Baseline Wound Size (length and width) at 2 months will be assessed in digital images taken of the wound.

    Time frame: At the beginning of the study (0 day) and at the end of the eighth week of the intervention (8 weeks)

  3. Visual Analog Scale changes for pain assessment

    Pain will be evaluated by the visual analog scale system (VAS) which assesses changes in pain via a continuous measurement instrument. The score is determined by measuring the distance (mm) between the no-pain anchor to the point that the patient marks, providing a range of scores from 0 - 10. A higher score indicates greater pain intensity.

    Time frame: Every 48 hours for 8 weeks

  4. Duration of recovery

    The duration of recovery, which is the number of days it will be taken for the wound to heal.

    Time frame: 8 weeks

  5. Change in the systemic inflammatory marker C-reactive protein (CRP)

    C-reactive protein (CRP)

    Time frame: At the beginning of the study (0 day) and at the end of the eighth week of the intervention (8 weeks)

  6. Change in systemic inflammatory marker erythrocyte sedimentation rate (ESR)

    erythrocyte sedimentation rate (ESR)

    Time frame: At the beginning of the study (0 day) and at the end of the eighth week of the intervention (8 weeks)

  7. Change in systemic inflammatory marker Interleukin 6 (IL-6)

    Interleukin 6 (IL-6)

    Time frame: At the beginning of the study (0 day) and at the end of the eighth week of the intervention (8 weeks)

  8. Number of participants with infection

    A swab culture: Identify a small area (1 cm) of clean viable tissue and rotate the swab on it for 5 seconds while applying enough pressure to produce exudate and culture it to detect bacteria.

    Time frame: At the beginning of the study (0 day) and at the end of the eighth week of the intervention (8 weeks)

  9. Results of the SF36 questionnaire at inclusion

    The SF-36 questionnaire is a quality-of-life questionnaire that includes 36 questions divided into 8 different categories (physical functioning, limitations due to physical condition, physical pain, perceived health, vitality, social functioning or well-being, limitations due to mental condition, mental health). These 8 dimensions are used to calculate two scores on the quality of life of individuals: the physical composite score and the mental composite score. The higher the score, the greater the capacity. It is self-administered and takes less than 10 minutes. Higher scores indicate better quality of life. The French version has been validated and has satisfactory psychometric properties. Score from 0 to 100.

    Time frame: Day 0

  10. Results of the SF36 questionnaire at Month 2

    The SF-36 questionnaire is a quality-of-life questionnaire that includes 36 questions divided into 8 different categories (physical functioning, limitations due to physical condition, physical pain, perceived health, vitality, social functioning or well-being, limitations due to mental condition, mental health). These 8 dimensions are used to calculate two scores on the quality of life of individuals: the physical composite score and the mental composite score. The higher the score, the greater the capacity. It is self-administered and takes less than 10 minutes. Higher scores indicate better quality of life. The French version has been validated and has satisfactory psychometric properties. Score from 0 to 100.

    Time frame: Month 2

Secondary outcomes

  1. Percentage rate of re-epithelialization

    Pictures taken of the wound site every other day will be analyzed using imaging software for the size of the wound. The percentage rate will be calculated from this.

    Time frame: Participants will be followed for the duration of 8 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — All data related to the project after the unidentifiable people will be shared.

Supporting information: Study protocol, Informed consent form

Time frame: Access to data is allowed 6 months after the publication of results.

Access criteria: The investigator's data will be available to university staff and academic institutions.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Jan 2024, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2023
First posted
Aug 9, 2023
StartActual
Aug 20, 2023
Primary completionActual
Jan 20, 2024
CompletionEst.
Mar 20, 2027
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05983302
Lead sponsor
Mashhad University of Medical Sciences
Responsible party
Daryoush Hamidi Alamdari, PhD (Professor, Mashhad University of Medical Sciences) — Principal investigator
First posted
Aug 9, 2023
Start date
Aug 20, 2023
Primary completion
Jan 20, 2024
Completion
Mar 20, 2027 (estimated)
Last update
May 6, 2026

Study contacts

Daryoush Hamidi Alamdari, Ph.D
principal investigator · Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Daryoush Hamidi Alamdari
principal investigator · Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion